株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

三次元細胞培養 (3D細胞培養) :製品・技術・主な応用領域 (第2版) 2017-2030年

3D Cell Cultures: Products, Technologies and Key Application Areas (2nd Edition), 2017-2030

発行 ROOTS ANALYSIS 商品コード 332052
出版日 ページ情報 英文 339 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
三次元細胞培養 (3D細胞培養) :製品・技術・主な応用領域 (第2版) 2017-2030年 3D Cell Cultures: Products, Technologies and Key Application Areas (2nd Edition), 2017-2030
出版日: 2017年09月28日 ページ情報: 英文 339 Pages
概要

当レポートでは、様々な足場型 (Scaffold Based) および浮遊型 (Scaffold Free) の三次元細胞培養システムについて調査し、三次元足場・マトリックスの製造方法、三次元細胞培養システムの分類、全体的な三次元細胞培養市場情勢のレビュー、主要ディベロッパーの包括的なプロファイル、流行・新興動向を反映するソーシャルメディアの分析、および市場予測などをまとめています。

第1章 序論

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 三次元細胞培養システムの分類

  • 三次元細胞培養の分類:概要
  • 足場型 (Scaffold Based) 三次元細胞培養
  • 浮遊型 (Scaffold Free) 三次元細胞培養
  • オルガノイド

第5章 三次元マトリックス・足場の製造方法

  • 本章の概要
  • 多孔質足場の製造方法
  • 繊維質足場の製造方法
  • ヒドロゲルの製造方法
  • カスタム足場の製造方法
  • ミクロスフェアの製造方法
  • 天然足場の製造方法

第6章 市場概要

  • 本章の概要
  • 三次元細胞培養製品:ヒドロゲル/細胞外マトリックス (ECM) 、細胞培養器具、およびバイオリアクターのリスト
  • 三次元細胞培養製品:アッセイキット、試薬、およびサービス

第7章 三次元細胞培養:主なアプリケーション領域

  • 本章の概要
  • 癌研究における三次元細胞培養
  • 創薬・毒性検査における三次元細胞培養システム
  • 幹細胞研究における三次元細胞培養システム
  • 再生医療・組織工学における三次元細胞培養システム
  • 三次元細胞培養システム:主なアプリケーション領域の分析

第8章 ソーシャルメディア上の三次元細胞培養における新興動向

  • 本章の概要
  • 三次元細胞培:ツイッター上の動向

第9章 三次元細胞培養製品:主要企業

  • 本章の概要
  • 三次元細胞培養製品およびECM/ヒドロゲルのディベロッパー
  • Organs-on-Chip (臓器チップ) のディベロッパー

第10章 三次元培養バイオリアクター:主要企業

  • 本章の概要

第11章 市場予測

  • 本章の概要
  • 主な前提条件・予測手法
  • 三次元細胞培養市場の予測

第12章 調査分析

第13章 結論

第14章 インタビュー記録

第15章 付録:図表

第16章 付録:企業・組織のリスト

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: RA10090

A number of research efforts in drug discovery are being directed towards the introduction of in vitro testing models that replicate the in vivo microenvironment and provide physiologically relevant insights. Cell culture monolayers or 2D cell cultures are known to harbor differences in morphology, growth rate, function, viability and the overall behavior, as compared to those in natural environment. However, it has been realized that 3D cell cultures facilitate cell interaction with the surrounding media in all the possible dimensions. Cells cultivated using 3D techniques provide an appropriate ecosystem for cells to grow and proliferate and, consequently generate more accurate results of the experiments conducted on them.

The 3D cell culture industry is currently characterized by presence of several scaffold-based and scaffold-free products and services, widely being used for the purpose of research across a variety of application areas. Examples of scaffold-based 3D culture products include solid scaffolds, hydrogels, ECM-coated plates and microcarriers. Products, such as hanging drop plates, ultra-low attachment surfaces, micropatterned plates and suspension culture systems (such as 3D bioreactors), are some of the important scaffold-free 3D technologies that are currently available. It is worth highlighting that despite the advantages that they offer, the adoption of 3D cell cultures is hindered by certain challenges. These cell culture systems are currently limited to small scale production of cells, thereby, restricting their use to research applications only. Moreover, 3D culture techniques still need to be optimized in order to ensure consistency of results generated across different scales of operation. Due to the aforementioned challenges, 2D cultures continue to be preferred over 3D culture systems; however, with increasing awareness of the advantages of 3D cultures, a significant proportion of researchers are anticipated to gradually transition towards 3D culture systems.

Synopsis:

It is well-known that, of the several drug / therapy candidates undergoing clinical evaluation, very few make it to advanced stages and an even lesser number receive regulatory approval. One of the key reasons for the failure of therapeutic candidates in clinical trials is the use of conventional 2D cell culture systems in early research studies. It is important to reiterate that these 2D systems are severely limited in a number of aspects. For instance, only 50% of the cell surface is exposed to the culture media; as a result, the actual responses of cells to specific modulators / stimulants cannot be accurately understood. It is also worth noting that attrition rates of close to 95% have been reported for anti-cancer drug candidates as a result of inaccurate in vitro drug efficacy results and unforeseen toxicity issues that were not properly assessed due to the limitation of 2D culture models. The use of advanced 3D cell culture techniques in in vitro studies is seen to have the capability to overcome several such challenges, currently associated with 2D systems.

The ‘3D Cell Cultures: Products, Technologies and Key Application Areas (2nd Edition), 2017-2030'report features an extensive study on the various scaffold-based and scaffold-free 3D culture systems. We identified over 80 hydrogel / ECM based products, 70 inserts / plates / other cultureware and 50 3D bioreactors that are widely being used for a variety of research applications across the globe. In addition, several kits, assays and tools are also available to carry out cytotoxicity assessments, transfections and cell viability testing. Amongst other elements, the report features:

  • An elaborate discussion on the methods used for fabrication of 3D scaffolds and matrices, highlighting the materials used, the process of fabrication, merits and demerits, and the applications of all of the methods.
  • An in-depth classification of 3D culture systems, which are categorized under scaffold-based systems (such as hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers) and scaffold-free (such as hanging drop plates, suspension culture systems and organ-on-chips) 3D culture systems.
  • A review of the overall landscape of the 3D cell culture market with respect to scaffold-format (scaffold-based / scaffold-free), product type (Hydrogels / ECMs, 3D cultureware, 3D bioreactors), product sub-type (hydrogels / ECMs are further classified on the basis of source and 3D cultureware on the basis of solid scaffolds, suspension culture systems, microfluidic systems, ECM-coated plates, attachment resistant cell culture plates, micropatterned surfaces) and product availability across different regions of the world.
  • Comprehensive profiles of the key developers (with two or more unique bioreactors in their portfolio) of 3D bioreactors, featuring a brief company overview, description of the product, advantages, applications, collaborations related to the product, and a comprehensive future outlook. Additionally, the report includes profiles of companies with more than five unique 3D culture products (inserts or plates or hydrogels) in their portfolio and those that specialize in the field of organ-on-chips.
  • A social media analysis depicting the prevalent and emerging trends, and the popularity of 3D cell cultures on the social media platform, Twitter. The analysis was carried out using tweets posted on the platform from 2008 to 2017.
  • An insightful analysis, highlighting the applications of each of the 3D culture products mentioned in the market landscape. The applications have been categorized under [A] Cancer research, [B] Drug discovery and toxicity screening, [C] Stem cell research, [D] Tissue engineering / regenerative medicine. Additionally, the section represents the distribution of each of the product segments across the aforementioned applications, highlighting the relevance of different types of products in biomedical research.

One of the key objectives of the report was to estimate the future size of the global 3D cell culture market. We adopted a top-down approach to evaluate the likely success and the growth of the market over the next 10-15 years. The insights generated on the future opportunity are segmented on the basis of applications areas, key geographies (the US, EU, Asia and the rest of the world), product type, scaffold format (scaffold-based versus scaffold-free) and the end use (research versus therapeutics). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios for the period 2017-2030, namely conservative, base and optimistic scenarios, which represent three different tracks of the industry's evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The report presents details of the conversations with (in alphabetical order of company name) Scott Brush (VP Sales and Marketing, BRTI Life Sciences), Jens Kelm (CSO, InSphero), Darlene Thieken (Project Manager, Nanofiber Solutions), Colin Sanctuary (Co-Founder and CEO, QGel), Bill Anderson (President / CEO, Synthecon), Anonymous (President and CEO, US based start-up), Anonymous (VP Technical, Business Operations & Co-Founder, US based company).

Example Highlights:

  • 1. Over 200 3D cell culture products are either commercially available or are under development; of these, ~60% use scaffold based while ~40% use scaffold free formats. Some products can be used as both scaffold based and scaffold free formats. Of the total number of 3D cell culture products, 40% are hydrogels / ECMs and 34% are 3D cultureware products. In addition to the aforementioned products, the 3D cell culture market includes several 3D bioreactors, which have emerged as important scaffold free systems to carry out large scale production.
  • 2. The market is characterized by the presence of nearly 125 players; in addition to industry stalwarts, the landscape features participation of several small-sized and mid-sized firms. Examples of small-sized companies that offer 3D culture products include (in alphabetical order) 3D BioMatrix, Celartia, Cellec Biotek, EBERS, Global Cell Solutions, Nanofiber Solutions, Nano3D Biosciences, PBS Biotech and RealBio Technology. Some of the mid-sized players that are active in this area include (in alphabetical order) 4titude®, Koken, MatTek Corporation, STEMCELL Technologies and TAP Biosystems. Examples of the established players include (in alphabetical order) Corning Life Sciences, EMD Millipore, GE Healthcare, Sigma-Aldrich and Thermo Fisher Scientific.
  • 3. An analysis on the social media platform, Twitter, reveals an increasing volume of tweets related to the 3D cell cultures; between 2008 and 2016, a CAGR of 57% was registered in the number of tweets. In the given time period, over 4000 relevant tweets were recorded; this clearly indicates an upsurge in the popularity of the 3D cell culture approaches.
  • 4. Over 90% of the overall 3D cell culture market is focused on research. However, as the challenges (such as lack of awareness, constraints in scalability and inconsistencies in system optimization) associated with the application of these robust culture systems are addressed, these systems are expected to be extensively used for the development, manufacturing and characterization of pharmacological interventions.
  • 5. Our outlook is highly promising as we anticipate the use of 3D cell culture systems across different application areas over the coming decade. In fact, we predict the market to grow at an annualized rate of over 20% till 2030. From a regional perspective, North America (specifically the US) is likely to maintain its domination in the future.
  • 6. Cancer research and drug discovery, with over 50% share, currently account for a significant portion of the market. As the research pace heightens, the use of 3D cell cultures in stem cell research and tissue engineering / regenerative medicine, currently representing a sizeable share, is also likely to expand aggressively.

Research Methodology:

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming 10-15 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 presents an executive summary of the report. It offers a high-level view on where the 3D cell cultures market is headed in the mid to long term.

Chapter 3 provides a general introduction to 3D culture systems. In this section, we have briefly discussed the different types of cell cultures, the various methods of cell culturing and their application areas. The chapter features a comparative analysis of 2D and 3D cultures, and highlights the current need and advantages of 3D culture systems.

Chapter 4 gives an overview of the classification of 3D culture systems. It highlights the different 3D culture technologies, classified under scaffold-based and scaffold-free systems. It also highlights, in detail, the underlying concepts, advantages and disadvantages of each sub-category of 3D systems.

Chapter 5 presents summaries of the different techniques that are utilized to fabricate various 3D scaffolds and matrices. It provides information on the working principle, and merits and demerits associated with these methods. It also presents the key takeaways from various research studies that were carried out on matrices fabricated using the aforementioned methods.

Chapter 6 provides comprehensive lists of the different 3D culture systems that are available in the market or are under development. The section also presents analyses of the products on the basis of scaffold type, product type (3D hydrogels and ECMs / 3D cultureware / 3D bioreactors) and product sub-type. In addition, the chapter provides information on the geographical presence of the developers of these 3D culture systems and details on the companies that offer 3D culture related services and associated consumables.

Chapter 7 presents a detailed overview on the most popular application areas, which include cancer research, drug discovery and toxicity screening, stem cell research and tissue engineering / regenerative medicine. It features an elaborate analysis, highlighting the application area(s) for all the products mentioned in the market landscape (Chapter 6). Additionally, the section features an illustrative representation of the product type(s) that are most widely used for a particular application.

Chapter 8 provides insights on the popularity of 3D cell cultures on the social media platform, Twitter. The section highlights the yearly distribution of tweets posted on the platform in the time period 2008-2017, and the most significant events responsible for increase / decrease in the volume of tweets each year, during the above-mentioned time period. Additionally, the chapter showcases the most talked about 3D culture products and application areas on social media.

Chapter 9 provides detailed profiles of the players with over five unique products in their 3D culture portfolio (hydrogels / ECMs and 3D cultureware). Each profile includes information on the developer, its product portfolio, recent collaborations and a discussion on the future outlook of the company. Additionally, the chapter includes profiles of prominent developers of organ-on-chips.

Chapter 10 presents detailed profiles of key players with more than two unique 3D bioreactors in their portfolio. Each profile includes a brief overview of the developer, information on the product portfolio and a discussion on the future outlook of the company.

Chapter 11 presents a comprehensive market forecast, highlighting the future potential of the market till 2030. The chapter presents a detailed market segmentation on the basis of product type (3D bioreactors, hydrogels / ECM, solid scaffolds, microfluidic plates, suspension culture systems), scaffold type (scaffold-based versus scaffold-free) and end use (research versus therapeutics) that are likely to contribute to the market in the coming decade. Additionally, the section highlights the contribution of different geographies (the North America, EU, Asia and rest of the world) in the 3D culture market.

Chapter 12 presents insights from the survey conducted for this study. We invited close to 100 stakeholders involved in the development of 3D cell culture systems. The participants, who were primarily Founder / CXO / Senior Management level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 13 summarizes the overall report. The chapter provides a list of the key takeaways and presents our independent opinion on the 3D cell cultures market, based on the research and analysis described in the previous chapters.

Chapter 14 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with (in alphabetical order of company name) Scott Brush (VP Sales and Marketing, BRTI Life Sciences), Jens Kelm (CSO, InSphero), Darlene Thieken (Project Manager, Nanofiber Solutions), Colin Sanctuary (Co-Founder and CEO, QGel), Bill Anderson (President / CEO, Synthecon), Anonymous (President and CEO, US based start-up), Anonymous (VP Technical, Business Operations & Co-Founder, US based company).

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Classification of Cell Cultures
    • 3.2.1. Primary Cell Cultures
    • 3.2.2. Cell Lines
  • 3.3. Morphology of Cells in Culture
  • 3.4. Transition from 2D to 3D Cell Culture
  • 3.5. The Concept of 3D Cell Culture
    • 3.5.1. Components of the Extra Cellular Matrix (ECM)
    • 3.5.2. In Vitro Cell Culture
    • 3.5.3. Selection of Culture Format
  • 3.6. Cell Cultures: Establishment and Maintenance
    • 3.6.1. Isolating Cells from Tissues
    • 3.6.2. Maintaining Cells in Culture
    • 3.6.3. Sub-Culturing
    • 3.6.4. Cryogenic Storage
    • 3.6.5. Cross-Contamination Concerns
  • 3.7. The Need for 3D Cell Culture Systems
    • 3.7.1. Model Systems
    • 3.7.2. Drug Discovery and Preclinical Research
    • 3.7.3. Cancer Research
    • 3.7.4. Virology Research
    • 3.7.5. Genetic Engineering and Gene Therapy Research
  • 3.8. Cell Culturing: Basic Requirements
    • 3.8.1. The Cell Culture Facility and Safety Guidelines
    • 3.8.2. Avoiding Contamination
    • 3.8.3. Cell Culture Health and Optimal Conditions
  • 3.9. 3D Cell Culture: Advantages and Limitations
  • 3.10. Future Landscape of 3D Cell Culture

4. CLASSIFICATION OF 3D CELL CULTURE SYSTEMS

  • 4.1. 3D Cell Culture Classification: An Overview
  • 4.2. Scaffold Based 3D Cell Cultures
    • 4.2.1. Hydrogels / Extra Cellular Matrix (ECM) Analogs
    • 4.2.2. Solid Scaffolds
    • 4.2.3. Micropatterned Surfaces
    • 4.2.4. Microcarriers
  • 4.3. Scaffold Free 3D Cell Cultures
    • 4.3.1. Attachment Resistant Surfaces
    • 4.3.2. Suspension Culture Systems
      • 4.3.2.1. Hanging Drop Plates
      • 4.3.2.2. 3D Bioreactors
      • 4.3.2.3. Magnetic Levitation and 3D Bioprinting
    • 4.3.3. Microfluidic Surfaces and Organs-on-Chips
  • 4.4. Organoids

5. METHODS USED FOR FABRICATION OF 3D MATRICES AND SCAFFOLDS

  • 5.1. Chapter Overview
  • 5.2. Methods for Fabricating Porous Scaffolds
    • 5.2.1. Particulate Leaching
    • 5.2.2. Solvent Casting
    • 5.2.3. Emulsion Templating
    • 5.2.4. Gas Foaming
    • 5.2.5. Melt Molding
    • 5.2.6. Microsphere Sintering
  • 5.3. Methods for Fabricating Fibrous Scaffolds
    • 5.3.1. Electrospinning
    • 5.3.2. Phase Separation
    • 5.3.3. Self-Assembly
    • 5.3.4. Fiber Mesh and Fiber Bonding
  • 5.4. Methods for Fabricating Hydrogels
    • 5.4.1. Gelation
    • 5.4.2. Solvent Casting and Particulate Leaching
    • 5.4.3. Gas Foaming
    • 5.4.4. Freeze Drying
    • 5.4.5. Co-Polymerization / Crosslinking
    • 5.4.6. Microfluidics
  • 5.5. Methods for Fabricating Custom Scaffolds
    • 5.5.1. Stereo-lithography
    • 5.5.2. 3D Bioprinting and Selective Laser Sintering (SLS)
    • 5.5.3. Fused Deposition Modeling
    • 5.5.4. Membrane Lamination
    • 5.5.5. Rapid Prototyping / Solid Free-Form (SFF) Technique
  • 5.6. Methods for Fabricating Microspheres
    • 5.6.1. Solvent Evaporation
    • 5.6.2. Single and Double Emulsification
    • 5.6.3. Particle Aggregation
  • 5.7. Methods for Fabricating Native Scaffolds
    • 5.7.1. Decellularization

6. MARKET OVERVIEW

  • 6.1. Chapter Overview
  • 6.2. 3D Cell Culture Products: List of Hydrogels / Extracellular Matrices (ECMs), Cultureware and Bioreactors
    • 6.2.1. 3D Cell Culture Products: Distribution by Type
    • 6.2.2. 3D Cell Culture Products: Distribution by Scaffold Format
    • 6.2.3. 3D Cell Culture Products: Distribution by Hydrogels / ECMs
    • 6.2.4. 3D Cell Culture Products: Distribution by Cultureware
    • 6.2.5. 3D Cell Culture Products: Most Active Players
    • 6.2.6. 3D Cell Culture Products: Geographical Landscape of Developers
  • 6.3. 3D Cell Culture Products: Assay Kits, Reagents and Services

7. 3D CELL CULTURE: KEY APPLICATION AREAS

  • 7.1. Chapter Overview
  • 7.2. 3D Cell Culture Systems in Cancer Research
    • 7.2.1. Reasons to Adopt 3D Cell Culture Systems in Cancer Research
    • 7.2.2. Improving Cancer Drug Screening with 3D Cell Culture Systems
  • 7.3. 3D Cell Culture Systems in Drug Discovery and Toxicity Screening
    • 7.3.1. Drug Development Studies
    • 7.3.2. Toxicity Screening
  • 7.4. 3D Cell Culture Systems in Stem Cell Research
    • 7.4.1. Potential of 3D Cell Culture Systems in Stem Cell Differentiation
    • 7.4.2. In Vitro 3D Microenvironment to Induce Embryoid Body Formation
  • 7.5. 3D Cell Culture Systems in Regenerative Medicine and Tissue Engineering
  • 7.6. 3D Cell Culture Systems: Analyses on Key Application Areas
    • 7.6.1. 3D Cell Culture Products: Distribution by Applications and Types
      • 7.6.1.1. Hydrogels / ECMs: Distribution by Applications
      • 7.6.1.2. 3D Cultureware: Distribution by Applications
      • 7.6.1.3. 3D Bioreactors: Distribution by Applications

8. EMERGING TRENDS IN 3D CELL CULTURE ON SOCIAL MEDIA

  • 8.1. Chapter Overview
  • 8.2. 3D Cell Culture: Trends on Twitter
    • 8.2.1. 3D Cell Culture: Yearly Distribution of Tweets
    • 8.2.2. 3D Cell Culture: Word Cloud Analysis
    • 8.2.3. 3D Cell Culture: Popular Product Types on Twitter, 2008-2017
    • 8.2.4. 3D Cell Culture: Popular Product Sub-types on Twitter, 2008-2017
    • 8.2.5. 3D Cell Culture: Popular Applications on Twitter, 2008-2017

9. 3D CELL CULTURE PRODUCTS: KEY PLAYERS

  • 9.1. Chapter Overview
  • 9.2. Developers of 3D Cultureware and ECMs / Hydrogels
    • 9.2.1. 3D Biotek
      • 9.2.1.1. Developer Overview
      • 9.2.1.2. Product Portfolio
      • 9.2.1.3. Future Outlook
    • 9.2.2. Advanced BioMatrix
      • 9.2.2.1. Developer Overview
      • 9.2.2.2. Product Portfolio
      • 9.2.2.3. Future Outlook
    • 9.2.3. Alphabioregen
      • 9.2.3.1. Developer Overview
      • 9.2.3.2. Product Portfolio
      • 9.2.3.3. Future Outlook
    • 9.2.4. Corning Life Sciences
      • 9.2.4.1. Company Overview
      • 9.2.4.2. Product Portfolio
      • 9.2.4.3. Future Outlook
    • 9.2.5. ReproCELL
      • 9.2.5.1. Developer Overview
      • 9.2.5.2. Product Portfolio
      • 9.2.5.3. Future Outlook
  • 9.3. Developers of Organs-on-Chips
    • 9.3.1. CN Bio Innovations
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Product Portfolio
    • 9.3.2. Emulate
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Product Portfolio
    • 9.3.3. InSphero
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Product Portfolio
    • 9.3.4. MIMETAS
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Product Portfolio
    • 9.3.5. Nortis
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Product Portfolio
    • 9.3.6. TissUse
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Product Portfolio

10. 3D CULTURE BIOREACTORS: KEY PLAYERS

  • 10.1. Chapter Overview
    • 10.2.1. Celartia
      • 10.2.1.1. Developer Overview
      • 10.2.1.2. Product Portfolio
      • 10.2.1.3. Future Outlook
    • 10.2.2. Cell Culture Company
      • 10.2.2.1. Developer Overview
      • 10.2.2.2. Product Portfolio
      • 10.2.2.3. Future Outlook
    • 10.2.3. CESCO BioProducts
      • 10.2.3.1. Developer Overview
      • 10.2.3.2. Product Portfolio
      • 10.2.3.3. Future Outlook
    • 10.2.4. China Regenerative Medicine International
      • 10.2.4.1. Company Overview
      • 10.2.4.2. Product Portfolio
      • 10.2.4.3. Future Outlook
    • 10.2.5. EBERS
      • 10.2.5.1. Developer Overview
      • 10.2.5.2. Product Portfolio
      • 10.2.5.3. Future Outlook
    • 10.2.6. PBS Biotech
      • 10.2.6.1. Developer Overview
      • 10.2.6.2. Product Portfolio
      • 10.2.6.3. Future Outlook
    • 10.2.7. Synthecon
      • 10.2.7.1. Developer Overview
      • 10.2.7.2. Product Portfolio
      • 10.2.7.3. Future Outlook

11. MARKET FORECAST

  • 11.1. Chapter Overview
  • 11.2. Key Assumptions and Methodology
  • 11.3. 3D Cell Culture Market Forecast, 2017-2030
    • 11.3.1. 3D Cell Culture Market Forecast: Distribution by Application
    • 11.3.2. 3D Cell Culture Market Forecast: Distribution by Scaffold Format
    • 11.3.3. 3D Cell Culture Market Forecast: Distribution by Product Type
    • 11.3.4. 3D Cell Culture Market Forecast: Distribution by Geography
    • 11.3.5. 3D Cell Culture Market Forecast: Distribution by End Use

12. SURVEY ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Overview of Respondents
  • 12.3. Focus Area of the Company
  • 12.4. Category of Lead Product(s)
  • 12.5. Nature of Matrices
  • 12.6. Development Status of Lead Product(s)
  • 12.7. Sources of 3D Cultured Cells
  • 12.8. Applications of 3D Cell Culture Products
  • 12.9. Likely Market Size

13. CONCLUSION

  • 13.1. 3D Cell Cultures, With Inherent Advantages over 2D Cell Cultures, are Gradually Gaining Attention in the Research Industry
  • 13.2. Most 3D Cell Cultures Require a Supporting Scaffold for Growth and Propagation; However, Scaffold Free Techniques are Available as Well
  • 13.3. Such Advanced Culture Systems have Found Use in a Myriad of Application Areas
  • 13.4. Despite the Ongoing Innovation, 3D Cell Cultures are Yet to Unveil Potential in Mainstream Therapeutics
  • 13.5. Post Mitigation of Associated Challenges, The Market is Likely to Witness a Higher Adoption
  • 13.6. Overall, the 3D Cell Culture Market is Likely to Emerge as a Multi-Billion Dollar Market in the Long Term

14. INTERVIEW TRANSCRIPTS

  • 14.1. Chapter Overview
  • 14.2. Bill Anderson, President and Chief Executive Officer, Synthecon
  • 14.3. Colin Sanctuary, Co-Founder and Chief Executive Officer, QGel
  • 14.4. Darlene Thieken, Senior Management, Nanofiber Solutions
  • 14.5. Jens Kelm, Chief Scientific Officer, InSphero
  • 14.6. Scott Brush, VP Sales and Marketing, BRTI Life Sciences
  • 14.7. Anonymous, President and Chief Executive Officer, Leading Company in 3D Cell Culture Domain
  • 14.8. Anonymous, VP-Technical, Business Operations & Co-Founder, Leading Company in 3D Cell Culture Domain

15. APPENDIX: TABULATED DATA

16. APPENDIX: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

  • Figure 3.1: Classifications of Cell Cultures
  • Figure 3.2: Types of Cell Culture Systems
  • Figure 3.3: Key Components of Extra Cellular Matrix(ECM)
  • Figure 3.4: Factors Influencing the Choice of 3D Cell Culture Systems
  • Figure 3.5: Methods of Cell Isolation from Tissues
  • Figure 3.6: Methods of Cryogenic Storage
  • Figure 3.7: Applications of Cell Culturing
  • Figure 3.8: 3D Spheroids Generated via 3D Cell Culture Systems
  • Figure 3.9: Cell Culture: Biosafety Levels
  • Figure 4.1: Classification of 3D Cell Culture Systems
  • Figure 4.2: Natural Components of Extracellular Matrix(ECM) for Fabrication of Scaffolds
  • Figure 4.3: Hydrogels: Advantages and Disadvantages
  • Figure 4.4: Microcarriers: Advantages
  • Figure 4.5: Techniques Used for Formation of Spheroids
  • Figure 4.6: Spinner Flask and Rotating Wall Bioreactors: Device Structure
  • Figure 6.1: 3D Cell Culture Products: Distribution by Type
  • Figure 6.2: 3D Cell Culture Products: Distribution by Scaffold Format
  • Figure 6.3: 3D Cell Culture Products: Distribution by Hydrogels / ECMs
  • Figure 6.4: 3D Cell Culture Products: Distribution by Cultureware
  • Figure 6.5: 3D Cell Culture Products: Most Active Players
  • Figure 6.6: 3D Cell Culture Products: Geographical Landscape of Developers
  • Figure 7.1: 3D Cell Culture: Key Applications
  • Figure 7.2: Reasons to Adopt 3D Cell Culture Systems in Cancer Research
  • Figure 7.3: 3D Cell Culture Systems in Drug Discovery and Toxicity Screening
  • Figure 7.4: 3D Cell Culture: Effect on Stem Cell Differentiation
  • Figure 7.5: Methods for Embryoid Body Formation
  • Figure 7.6: Tissue Engineering: Top-Down and Bottom-Up Approach
  • Figure 7.7: 3D Cell Culture Products: Distribution by Applications and Types
  • Figure 7.8: Hydrogels / ECMs: Distribution by Applications and Sub-types
  • Figure 7.9: 3D Cultureware: Distribution by Applications and Sub-types
  • Figure 7.10: 3D Bioreactors: Distribution by Applications
  • Figure 8.1: 3D Cell Culture: Yearly Distribution of Tweets, 2008-2017
  • Figure 8.2: 3D Cell Culture: Historical Trends by Twitter Volume, 2008-2017
  • Figure 8.3: 3D Cell Culture: Popular Keywords on Twitter, 2008-2017
  • Figure 8.4: 3D Cell Culture: Popular Product Types on Twitter, 2008-2017
  • Figure 8.5: 3D Cell Culture: Popular Product Sub-types on Twitter, 2008-2017
  • Figure 8.6: 3D Cell Culture: Popular Organ-on-Chip Models on Twitter, 2008-2017
  • Figure 8.7: 3D Cell Culture: Popular Applications on Twitter, 2008-2017
  • Figure 9.1: ReproCELL: Types of Alvetex® 3D Cell Culture Products
  • Figure 10.1: PetakaG3™ Bioreactors: Design Description
  • Figure 10.2: Cell Culture Company Perfusion Bioreactors: Features
  • Figure 10.3: MagDrive and AirDrive Mechanisms
  • Figure 10.4: Rotary Cell Culture System(RCCS): Advantages
  • Figure 11.1: 3D Cell Culture Market(2017-2030): Base Scenario(USD Billion)
  • Figure 11.2: 3D Cell Culture Market(2017-2030): Distribution by Application(USD Billion)
  • Figure 11.3: 3D Cell Culture Market: Share by Application, 2017, 2030(%)
  • Figure 11.4: 3D Cell Culture Market: Share by Scaffold Format, 2017(USD Billion)
  • Figure 11.5: 3D Cell Culture Market: Share by Product Type, 2017(%)
  • Figure 11.6: 3D Cell Culture Market: Share by Geography, 2017, 2030(%)
  • Figure 11.7: 3D Cell Culture Market: Share by End Use, 2017, 2030(%)
  • Figure 11.8: 3D Cell Culture Market: Leading Players, 2017(%)
  • Figure 12.1: Survey Analysis: Distribution by Type of Company
  • Figure 12.2: Survey Analysis: Distribution by Location of Respondents
  • Figure 12.3: Survey Analysis: Distribution by Seniority Level of Respondents
  • Figure 12.4: Survey Analysis: Distribution by Focus Area of the Company
  • Figure 12.5: Survey Analysis: Category of Lead Product(s)
  • Figure 12.6: Survey Analysis: Nature of Matrices
  • Figure 12.7: Survey Analysis: Status of Development of Lead Product(s)
  • Figure 12.8: Survey Analysis: Source of 3D Cultured Cells
  • Figure 12.9: Survey Analysis: Distribution by Application of 3D Cell Culture Products
  • Figure 12.10: Survey Analysis: Distribution by Likely Size of 3D Cell Culture Market
  • Figure 13.1: Overall 3D Cell Culture Market: Conservative, Base and Optimistic Scenarios, 2017-2030(USD Billion)

List of Tables:

  • Table 3.1: Morphology of Cells in a Culture
  • Table 3.2: Differences between 2D and 3D Cell Cultures
  • Table 3.3: Features of 3D Spheroids Generated via 3D Cell Culture Systems
  • Table 4.1: Scaffold Based and Scaffold Free Systems: Advantages and Disadvantages
  • Table 4.2: Natural and Synthetic Scaffolds: Advantages and Disadvantages
  • Table 4.3: Natural and Synthetic Hydrogels: Advantages and Disadvantages
  • Table 4.4: Cell Cultures Used in Magnetic Levitation
  • Table 4.6: Organoids: Origin and Culture Techniques
  • Table 5.1: Methods for Fabrication of Porous Scaffolds: Merits and Demerits
  • Table 5.2: 3D Cell Culture Studies Using Porous Scaffolds
  • Table 5.3: Methods for Fabrication of Fibrous Scaffolds
  • Table 5.4: Methods for Fabrication of Fibrous Scaffolds: Merits and Demerits
  • Table 5.5: 3D Cell Culture Studies Using Fibrous Scaffolds
  • Table 5.6: Methods for Fabrication of Hydrogels: Merits and Demerits
  • Table 5.7: 3D Cell Culture Studies Using Hydrogels
  • Table 5.8: Fabrication of Custom Scaffolds: Merits and Demerits
  • Table 5.9: 3D Cell Culture Studies Using Custom Scaffolds
  • Table 5.10: Fabrication of Microspheres: Merits and Demerits
  • Table 5.11: 3D Cell Culture Studies Using Microspheres
  • Table 5.12: 3D Cell Culture Studies Using Native Scaffolds
  • Table 6.1: 3D Cell Culture Products: List of Hydrogels / ECM
  • Table 6.2: 3D Cell Culture Products: List of Cultureware
  • Table 6.3: 3D Cell Culture Products: List of Bioreactors
  • Table 6.4: 3D Cell Culture Products: List of Assay Kits and Reagents
  • Table 6.5: 3D Cell Culture Products: List of Services
  • Table 7.1: 3D Cell Culture Products: Applications of Hydrogels / Extra Cellular Matrices(ECMs)
  • Table 7.2: 3D Cell Culture Products: Applications of 3D Cultureware
  • Table 7.3: 3D Cell Culture Products: Applications of 3D Bioreactors
  • Table 7.4: Hydrogels / ECM: Applications of Sub-types
  • Table 7.5: 3D Cultureware: Applications of Sub-types
  • Table 7.6: 3D Bioreactors: Applications
  • Table 9.1: 3D Cell Cultureware and ECM: List of Players Profiled
  • Table 9.2: 3D Biotek: Specifications of 3D Insert™-PS
  • Table 9.3: 3D Biotek: Specifications of 3D Insert™-PCL
  • Table 9.4: Advanced BioMatrix: Specifications of PureCol® Collagen Coated T-25 Flasks
  • Table 9.5: Advanced BioMatrix: Specifications of PureCol® Collagen Coated Well Plates
  • Table 9.6: Advanced BioMatrix: Specifications of PureCol® Collagen Coated Dishes
  • Table 9.7: Advanced BioMatrix: Specifications of AlignCol®
  • Table 9.8: Advanced BioMatrix: Specifications of FibriCol®
  • Table 9.9: Advanced BioMatrix: Specifications of FlexiCol®
  • Table 9.10: Advanced BioMatrix: Specifications of Nutragen®
  • Table 9.11: Advanced BioMatrix: Specifications of PureCol®
  • Table 9.12: Advanced BioMatrix: Specifications of RatCol® Rat Tail Collagen I
  • Table 9.13: Advanced BioMatrix: Specifications of SphereCol®
  • Table 9.14: Advanced BioMatrix: Specifications of SpongeCol®
  • Table 9.15: Advanced BioMatrix: Specifications of TeloCol®
  • Table 9.16: Advanced BioMatrix: Specifications of VitroCol®
  • Table 9.17: Alphabioregen: Specifications of Hydrogel Coated Plates
  • Table 9.18: Alphabioregen: Specifications of Collagen Coated Plates
  • Table 9.19: Alphabioregen: Specifications of Matrix Coated Plates
  • Table 9.20: Alphabioregen: Specifications of Poly-L-Lysine Coated Plates
  • Table 9.21: Alphabioregen: Specifications of AlphaBioGel Products
  • Table 9.22: Alphabioregen: Specifications of Collagel Hydrogel Products
  • Table 9.23: Corning Life Sciences: Specifications of Corning® BioCoat™ Cultureware
  • Table 9.24: Corning Life Sciences: Specifications of Corning® CellBIND® Surface
  • Table 9.25: Corning Life Sciences: Specifications of Corning® Osteo Assay Surface Cultureware
  • Table 9.26: Corning Life Sciences: Specifications of Corning® Primaria™ Surface
  • Table 9.27: Corning Life Sciences: Specifications of Corning® PureCoat™ Cultureware
  • Table 9.28: Corning Life Sciences: Specifications of Corning® Spheroid Microplates
  • Table 9.29: Corning Life Sciences: Specifications of Permeable Supports
  • Table 9.30: Corning Life Sciences: Specifications of Corning® Collagen Products
  • Table 9.31: Corning Life Sciences: Specifications of Corning® Laminin Products
  • Table 9.32: Corning Life Sciences: Specifications of Corning® Matrigel Matrices
  • Table 9.33: Corning Life Sciences: Specifications of Other Extra Cellular Matrix Based Products
  • Table 9.34: ReproCELL: Specifications of Alvetex® Scaffold Multiwell Plate Formats
  • Table 9.35: ReproCELL: Specifications of Alvetex® Scaffold / Strata Well Insert
  • Table 9.36: ReproCELL: Specifications of Alvetex® Tools
  • Table 9.37: ReproCELL: Specifications of EZSPHERE® Products
  • Table 9.38: ReproCELL: Formats of EZSPHERE® Products
  • Table 9.39: ReproCELL: Specifications of Atelocollagen and Collagen Products
  • Table 10.1: 3D Cell Culture Bioreactors: Companies Profiled
  • Table 10.2: Celartia: Features of PetakaG3™ Bioreactors
  • Table 10.3: Celartia: Specifications of PetakaG3™ ET Bioreactors
  • Table 10.4: Celartia: Specifications of PetakaG3™ HOT Bioreactors
  • Table 10.5: Cell Culture Company: Specifications of AutovaxID Bioreactor
  • Table 10.6: Cell Culture Company: Specifications of Maximizer Bioreactor
  • Table 10.7: Cell Culture Company: Specifications of MicroBrx Bioreactor
  • Table 10.8: Cell Culture Company: Specifications of Primer Bioreactor
  • Table 10.9: Cell Culture Company: Specifications of Xcellerator Bioreactor
  • Table 10.10: CESCO BioProducts: Specifications of BelloCell® Bioreactor
  • Table 10.11: EBERS: Specifications of TEB500 Series Bioreactor
  • Table 10.12: EBERS: Specifications of TEB1000 Series Bioreactor
  • Table 10.13: EBERS: Specifications of TC-3F Load Bioreactor
  • Table 10.14: PBS Biotech: Features of PBS Bioreactor Series with Dual Mechanism
  • Table 10.15: PBS Biotech: PBS MINI(PBS 0.1Mag / PBS 0.5Mag) Bioreactor
  • Table 10.16: PBS Biotech: Specifications of PBS 3(PBS 3Air / PBS 3Mag) Bioreactor
  • Table 10.17: PBS Biotech: Specifications of PBS 15(PBS 15Air / PBS 15Mag) Bioreactor
  • Table 10.18: PBS Biotech: Specifications of PBS 80(PBS 80Air / PBS 80Mag) Bioreactor
  • Table 10.19: PBS Biotech: Specifications of PBS 500 Bioreactor
  • Table 10.20: Synthecon: Specifications of Autoclavable Bioreactors(RCCS-1)
  • Table 10.21: Synthecon: Specifications of Autoclavable Bioreactors(RCCS-4H / RCCS-4HD)
  • Table 10.22: Synthecon: Specifications of Perfusion Bioreactors(RCCMax / RCCMax Dual)
  • Table 10.23: Synthecon: Specifications of Single Use / Disposable Bioreactors(RCCS-D / RCCS-2D)
  • Table 10.24: Synthecon: Specifications of Single Use / Disposable Bioreactors(RCCS-4D / RCCS-4DQ)
  • Table 10.25: Synthecon: Specifications of Stem Cell Bioreactor(RCCS-1SC / RCCS-2SC)
  • Table 10.26: Synthecon: Specifications of Stem Cell Bioreactor(RCCS-4SC / RCCS- 4SCQ)
  • Table 12.1: Survey Response: Overview of the Participating Companies
  • Table 12.2: Survey Response: Overview of Respondents
  • Table 12.3: Survey Response: Focus Area of the Company
  • Table 12.4: Survey Response: Category of Lead Product(s)
  • Table 12.5: Survey Response: Nature of Matrices
  • Table 12.6: Survey Response: Development Status of Lead Product(s)
  • Table 12.7: Survey Response: Source of 3D Cultured Cells
  • Table 12.8: Survey Response: Applications of 3D Cell Culture Products
  • Table 12.9: Survey Response: Likely Size of 3D Cell Culture Market
  • Table 15.1: 3D Cell Culture Products: Distribution by Type
  • Table 15.2: 3D Cell Culture Products: Distribution by Scaffold Format
  • Table 15.3: 3D Cell Culture Products: Distribution by Hydrogels / ECMs
  • Table 15.4: 3D Cell Culture Products: Distribution by Cultureware
  • Table 15.5: 3D Cell Culture Products: Most Active Players
  • Table 15.6: 3D Cell Culture Products: Distribution by Applications and Types
  • Table 15.7: 3D Cell Culture: Popular Product Types on Twitter, 2008-2017
  • Table 15.8: 3D Cell Culture: Popular Organ-on-Chip Models on Twitter, 2008-2017
  • Table 15.9: 3D Cell Culture Market(2017-2030): Base Scenario(USD Billion)
  • Table 15.10: 3D Cell Culture Market(2017-2030): Optimistic Scenario(USD Billion)
  • Table 15.11: 3D Cell Culture Market(2017-2030): Conservative Scenario(USD Billion)
  • Table 15.12: 3D Cell Culture Market(2017-2030): Distribution by Application(USD Billion)
  • Table 15.13: 3D Cell Culture Market: Share by Application, 2017, 2030(%)
  • Table 15.14: 3D Cell Culture Market: Share by Scaffold Format, 2017(USD Billion)
  • Table 15.15: 3D Cell Culture Market: Share by Product Type, 2017(%)
  • Table 15.16: 3D Cell Culture Market: Share by Geography, 2017, 2030(%)
  • Table 15.17: 3D Cell Culture Market: Share by End Use, 2017, 2030(%)
  • Table 15.18: 3D Cell Culture Market: Leading Players, 2017(%)
  • Table 15.19: Survey Analysis: Distribution by Type of Company
  • Table 15.20: Survey Analysis: Distribution by Location of Respondents
  • Table 15.21: Survey Analysis: Distribution by Seniority Level of Respondents
  • Table 15.22: Survey Analysis: Distribution by Focus Area of the Company
  • Table 15.23: Survey Analysis: Category of Lead Product(s)
  • Table 15.24: Survey Analysis: Nature of Matrices
  • Table 15.25: Survey Analysis: Status of Development of Lead Product(s)
  • Table 15.26: Survey Analysis: Source of 3D Cultured Cells
  • Table 15.27: Survey Analysis: Distribution by Application of 3D Cell Culture Products
  • Table 15.28: Survey Analysis: Distribution by Likely Size of 3D Cell Culture Market
  • Table 15.29: Overall 3D Cell Culture Market: Conservative, Base and Optimistic Scenarios, 2017-2030(USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report:

  • 1. 101Bio
  • 2. 3D Biomatrix
  • 3. 3D Biotek
  • 4. 4titude®
  • 5. AbbVie
  • 6. Accellta
  • 7. ACEA Biosciences
  • 8. Advanced BioMatrix
  • 9. AIM Biotech
  • 10. AK Biomedical
  • 11. Akron Biotech
  • 12. Alnylam Pharmaceuticals
  • 13. Alphabioregen
  • 14. AMS Biotechnology
  • 15. Antleron
  • 16. Applikon Biotechnology
  • 17. ARL Designs
  • 18. AstraZeneca
  • 19. AUCTEQ Biosystems
  • 20. AvantiCell Science
  • 21. AxoSim
  • 22. Bangalore Integrated System Solutions Tissue Growth Technologies (BiSS TGT)
  • 23. BASF
  • 24. BD Biosciences
  • 25. BellBrook Labs
  • 26. Benitec Biopharma
  • 27. Bio-Byblos Biomedical
  • 28. BioCellChallenge
  • 29. BioConnect
  • 30. Biogelx
  • 31. Biomaterials
  • 32. BioMedical Tissues
  • 33. Biomerix
  • 34. Biomimiq
  • 35. Biopta
  • 36. Biotronix
  • 37. Boston Institute of Biotechnology
  • 38. Bristol-Myers Squibb
  • 39. BRTI Life Sciences
  • 40. Celartia
  • 41. Celenys
  • 42. Cell Culture Company
  • 43. Cellec Biotek
  • 44. Cellendes
  • 45. Cellevate
  • 46. CellSpring
  • 47. CellSystems
  • 48. CelVivo
  • 49. CESCO BioProducts
  • 50. Cherry Biotech
  • 51. China Regenerative Medicine International
  • 52. China Stem Cell Clinical Applications Centre
  • 53. CN Bio Innovations
  • 54. Corning Life Sciences
  • 55. Cosmo Bio
  • 56. Covance
  • 57. Cyprotex
  • 58. CYTOO
  • 59. Dunn Labortechnik
  • 60. Durham University
  • 61. East River BioSolutions
  • 62. EBERS
  • 63. Ectica Technologies
  • 64. EMD Millipore
  • 65. Emulate
  • 66. EPISKIN
  • 67. Epithelix
  • 68. Eppendorf
  • 69. ESI BIO
  • 70. ETH Zurich
  • 71. Fennik Life Sciences
  • 72. FiberCell Systems
  • 73. Fraunhofer IGB
  • 74. Fraunhofer IWS
  • 75. FUJIFILM
  • 76. GE Healthcare
  • 77. GeneON
  • 78. GlaxoSmithKline
  • 79. Global Cell Solutions
  • 80. Greiner Bio-One
  • 81. HμREL® Corporation
  • 82. Hamilton Company
  • 83. HK International Regenerative Centre
  • 84. Hokkaido Soda
  • 85. Humeltis
  • 86. Imperial College London
  • 87. InSphero
  • 88. Instron
  • 89. InvitroCue
  • 90. InvivoSciences
  • 91. Iris Biosciences
  • 92. Japan Vilene
  • 93. Johnson & Johnson
  • 94. J-TEC
  • 95. KU Leuven
  • 96. Kirkstall
  • 97. KIYATEC
  • 98. Koken
  • 99. Kollodis BioSciences
  • 100. Kuraray
  • 101. LAMBDA Laboratory Instruments
  • 102. Leibniz Research Centre for Working Environment and Human Factors
  • 103. Lena Biosciences
  • 104. LFB Biomanufacturing
  • 105. Life Technologies
  • 106. Lifecore Biomedical
  • 107. Linari Engineering
  • 108. Locate Therapeutics
  • 109. Lonza
  • 110. LuoLabs
  • 111. Massachusetts Institute of Technology
  • 112. MatTek
  • 113. MBL International
  • 114. MD Biosciences
  • 115. Menicon Life Science
  • 116. Merck
  • 117. MicroTissues
  • 118. MIMETAS
  • 119. Mirus Bio
  • 120. MRC Centre for Drug Safety Science
  • 121. Nano3D Biosciences
  • 122. Nanofiber Solutions
  • 123. Nanogaia
  • 124. National Cancer Institute
  • 125. NC3Rs
  • 126. Neuromics
  • 127. Nortis
  • 128. Novadip
  • 129. ORGANOGENIX
  • 130. Organovo
  • 131. PBS Biotech
  • 132. PELOBiotech
  • 133. PepGel
  • 134. Percell Biolytica
  • 135. Pfizer
  • 136. Pishon Biomedical
  • 137. Pluristem Therapeutics
  • 138. ProBioGen
  • 139. Promega
  • 140. ProSys
  • 141. Protista
  • 142. QGel Bio
  • 143. Quinxell Technologies
  • 144. Radboudumc
  • 145. RealBio Technology
  • 146. RegeneMed
  • 147. Reinnervate
  • 148. ReproCELL
  • 149. Roche
  • 150. Sanofi
  • 151. Sarstedt
  • 152. Sartorius Stedim Biotech
  • 153. SCIVAX Life Sciences
  • 154. Seres Therapeutics
  • 155. Sigma-Aldrich
  • 156. SKE Research Equipment
  • 157. SkinAxis
  • 158. SoloHill Engineering
  • 159. SpheriTech
  • 160. StemCell Systems
  • 161. STEMCELL Technologies
  • 162. Stemmatters
  • 163. Stratatech
  • 164. StratiCELL
  • 165. Sumitomo Bakelite
  • 166. SUN Bioscience
  • 167. Synthecon
  • 168. SynVivo
  • 169. TAP Biosystems
  • 170. TARA Biosystems
  • 171. The Well Bioscience
  • 172. Thermo Fisher Scientific
  • 173. Tianjin Weikai Bioeng
  • 174. TissueClick
  • 175. TissUse
  • 176. Trevigen
  • 177. TU Berlin
  • 178. TU Dortmund
  • 179. UB-Care
  • 180. Univalor
  • 181. University College London
  • 182. University of Liverpool
  • 183. University of Oxford
  • 184. University of Pittsburgh
  • 185. University of Zaragoza
  • 186. University of Zurich
  • 187. University of Würzburg
  • 188. UPM Biochemicals
  • 189. Utrecht University
  • 190. Viscofan BioEngineering
  • 191. Vivo Biosciences
  • 192. Wyss Institute at Harvard University
Back to Top